Produktart
Zustand
Einband
Weitere Eigenschaften
Gratisversand
Land des Verkäufers
Verkäuferbewertung
Verlag: Marshall Cavendish Corporation, 1991
ISBN 10: 1854353861ISBN 13: 9781854353863
Anbieter: Better World Books, Mishawaka, IN, USA
Buch
Zustand: Very Good. Reference ed. Used book that is in excellent condition. May show signs of wear or have minor defects.
Mehr Angebote von anderen Verkäufern bei ZVAB
Gebraucht ab EUR 3,80
Verlag: Cavendish Square Publishing LLC, 2002
ISBN 10: 076141360XISBN 13: 9780761413608
Anbieter: Better World Books, Mishawaka, IN, USA
Buch
Zustand: Good. 2nd Edition. Former library book; may include library markings. Used book that is in clean, average condition without any missing pages.
Verlag: Graphic Arts Center Publishing Company, 1995
ISBN 10: 1558682465ISBN 13: 9781558682467
Buch
Zustand: Good. Good condition. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains. Bundled media such as CDs, DVDs, floppy disks or access codes may not be included.
Verlag: Cavendish Square Publishing LLC, 2002
ISBN 10: 0761415009ISBN 13: 9780761415008
Anbieter: Better World Books, Mishawaka, IN, USA
Buch
Zustand: Good. 2nd ed. Former library book; may include library markings. Used book that is in clean, average condition without any missing pages.
Verlag: Firebird, 2009
ISBN 10: 0142405523ISBN 13: 9780142405529
Buch
Zustand: Good. Good condition. Good dust jacket. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains. Bundled media such as CDs, DVDs, floppy disks or access codes may not be included.
Verlag: Graphic Arts Center Pub Co, 1997
ISBN 10: 1857331508ISBN 13: 9781857331509
Anbieter: WorldofBooks, Goring-By-Sea, WS, Vereinigtes Königreich
Buch
Paperback. Zustand: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.
Verlag: Altman Publishing 01/03/2001, 2001
ISBN 10: 1860360173ISBN 13: 9781860360176
Anbieter: AwesomeBooks, Wallingford, Vereinigtes Königreich
Buch
Zustand: Very Good. This book is in very good condition and will be shipped within 24 hours of ordering. The cover may have some limited signs of wear but the pages are clean, intact and the spine remains undamaged. This book has clearly been well maintained and looked after thus far. Money back guarantee if you are not satisfied. See all our books here, order more than 1 book and get discounted shipping. .
Verlag: Cavendish Square Publishing LLC, 2002
ISBN 10: 0761413626ISBN 13: 9780761413622
Anbieter: Better World Books, Mishawaka, IN, USA
Buch
Zustand: Good. Former library book; may include library markings. Used book that is in clean, average condition without any missing pages.
Verlag: Cavendish Square Publishing LLC, 2013
ISBN 10: 1608708705ISBN 13: 9781608708703
Anbieter: Better World Books, Mishawaka, IN, USA
Buch
Zustand: Good. 3rd ed. Former library book; may include library markings. Used book that is in clean, average condition without any missing pages.
Mehr Angebote von anderen Verkäufern bei ZVAB
Gebraucht ab EUR 15,28
Verlag: Goldmann, 2001
ISBN 10: 344244845XISBN 13: 9783442448456
Anbieter: DER COMICWURM - Ralf Heinig, Hohnhorst, DE, Deutschland
Buch
Taschenbuch. Zustand: Gut. ---. nein.
Verlag: München : Goldmann, 1999
ISBN 10: 3442350670ISBN 13: 9783442350674
Anbieter: Bücher bei den 7 Bergen, Sibbesse OT Westfeld, Deutschland
Buch
brosch. Zustand: Akzeptabel. Dt. Erstveröff. 569 S. ; 19 cm Bibliotheksexemplar mit Signatur und Stempel, Kanten berieben, sonst ordentlicher Zustand. EH1911 Sprache: Deutsch Gewicht in Gramm: 340.
Verlag: Rheda-Wiedenbrück : Bertelsmann-Club - Wien : Buchgemeinschaft Donauland Kremayr und Scheriau [u.a.], 1995
Anbieter: Antiquariat Buchhandel Daniel Viertel, Diez, Deutschland
Buch
8°, gebundene Ausgabe. Zustand: Gut. 543 S. ; 22 cm Exemplar gut erhalten, Mit Original Schutzumschlag, jedoch mit Gebrauchsspuren, 6539 Sprache: Deutsch Gewicht in Gramm: 718 Ungekürzte Buchgemeinschafts-Lizenzausg. Club-Premiere.
Verlag: Graphic Arts Center Publishing Company, 1998
Anbieter: biblion2, Obersulm, Deutschland
Zustand: Good. Taschenbuch. Zustandsangabe altersgemäß. Sofortversand aus Deutschland. Artikel wiegt maximal 500g. 272 Seiten. Englisches Exemplar. Vorsatz beschriftet.
Verlag: Machandel-Verlag, 2022
ISBN 10: 3959593368ISBN 13: 9783959593366
Anbieter: moluna, Greven, Deutschland
Buch
Zustand: New. KlappentextrnrnChinesische Drachen moegen ja Menschen freundlich gesinnt sein. Das heisst aber noch lange nicht, dass sie sich alles gefallen lassen. Nicht umsonst haben sie schliesslich Zaehne.nUeber das, was die Menschen unserer Zeit anstellen, sch.
Verlag: Taylor & Francis, 2009
ISBN 10: 0415363934ISBN 13: 9780415363938
Anbieter: moluna, Greven, Deutschland
Buch
Kartoniert / Broschiert. Zustand: New.
Verlag: Taylor & Francis, 2018
ISBN 10: 1138380512ISBN 13: 9781138380516
Anbieter: moluna, Greven, Deutschland
Buch
Gebunden. Zustand: New.
Verlag: Springer US, 2012
ISBN 10: 1461379164ISBN 13: 9781461379164
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiments.
Verlag: Springer US, 1997
ISBN 10: 0792342607ISBN 13: 9780792342601
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiments.